Skip to main content
. 2004 Nov 22;167(4):723–734. doi: 10.1083/jcb.200405144

Figure 5.

Figure 5.

Oct-4(+)/PAR-4(+) cells persist in teratomas from brain transplants of untreated EBCs. (A) Mouse EBs were incubated with or without 80 μM of the novel ceramide analogue S18 and 100,000 untreated (left) or 200,000 S18-treated (right) EBCs injected into the striatum of C57BL6 mice (right hemisphere, arrow shows injection site). After 6 wk, mice were killed and teratoma formation was analyzed (some mice had to be killed earlier to avoid distress to the animal). (B) The teratoma obtained with untreated EBCs (left; Fig. 1 A) was vibratome sectioned and the sections immunostained for the endodermal marker α-fetoprotein (AFP, Cy2, green), the mesodermal marker desmin (Cy3, red), the ectodermal marker vimentin (Cy5, blue, middle), and the neuro-ectodermal and glial marker GFAP (Cy5, blue, right). (C) Immunohistochemistry was also performed for nestin (Cy3, red) and PAR-4 (Cy2, green). (D) Immunostaining of nestin (Cy3, red), PAR-4 (Cy2, green), and Oct-4 (Cy5, red) at higher magnification.